Skip to main content

Table 1 Baseline characteristics and pulmonary function parameters by study group

From: Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD

Characteristic

COPD (N = 17)

NOS (N = 16)

NS (N = 13)

p-value

Male gender, n (%)

15 (88)

16 (100)

5 (38)

< 0.001

Age, years

64.4 ± 7

61.0 ± 11

61 ± 14

0.617

BMI, kg/m2

25.4 ± 4.2

27.4 ± 4.5

27.2 ± 4.2

0.364

Current smokers, n (%)

3 (17)

9 (56)

< 0.001

Pack-years

51.47 ± 15.52

39.87 ± 19.09

0.072

Diabetes Mellitus, n (%)

1 (6)

6 (37.5)

0.005

Fast basal glucose, mmol/L

5.2 [4.7–6.6]

6.5 [5.2–7.3]

5.3 [4.9–6.3]

0.056

Systemic hypertension, n (%)

8 (34.8)

7 (43.7)

5 (31.3)

0.896

Inhaled CS, n (%)

5 (29.0)

0 (0)

1 (7)

0.039

FVC, L

3.3 ± 0.7

4 ± 0.9

3.5 ± 1

0.079

FVC, % predicted

89 ± 14

101 ± 17

111 ± 23

0.008

FEV1, L

1.9 ± 0.5

3 ± 0.6

2.7 ± 0.8

< 0.001

FEV1, % predicted

64 ± 16

97 ± 14

106 ± 23

< 0.001

% FEV1/FVC

57 ± 10

76 ± 5

77 ± 5

< 0.001

DLCO,% predicted

69 ± 14

89 ± 17

93 ± 18

< 0.001

Leukocytes count, x10E9/L

8.7 ± 1.9

8.2 ± 2

6.9 ± 1.5

0.038

C-reactive protein, mg/L

5.4 [2.1–10.6]

2.1 [1.0–10.9]

1.8 [1–2.7]

0.028

  1. Data are presented as mean ± SD or median [25th–75th percentile]
  2. COPDChronic Obstructive Pulmonary Disease, NOS Non-obstructed smokers, NS Never smokers, BMI Body mass index, CS Corticosteroids, FVC Forced vital capacity, FEV 1 Forced expiratory volume in one second, DL CO Diffusing lung capacity for carbon monoxide. A p-value < 0.05 was considered statistically significant